Literature DB >> 32005973

AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics.

Miao Qi1, Dan Dai1, Jin Liu1, Zhongqi Li1, Panpan Liang1, Yue Wang1, Lu Cheng1, Yihong Zhan1, Zhifeng An1, Yaoyao Song1, Yana Yang1, Xiaohui Yan1, Hui Xiao1, Huanjie Shao2.   

Abstract

Mitochondrial fusion and fission dynamics fine-tune cellular calcium homeostasis, ATP production capacity and ROS production and play important roles in cell proliferation and migration. Dysregulated mitochondrial dynamics is closely related to tumor development, but the mechanism of mitochondrial dynamics dysregulation and its role in the development of lung cancer remains unclear. Here, we demonstrate that the DNA sensor protein absent in melanoma 2 (AIM2) is highly expressed in non-small cell lung cancer (NSCLC) cells and that high AIM2 expression is associated with poor prognosis in patients with NSCLC. High expression of AIM2 contributes to tumor cell growth and proliferation independent of inflammasome activation in vitro and in vivo. Further studies have shown that AIM2 colocalizes with mitochondria in NSCLC cells and that AIM2 knockdown leads to enhanced mitochondrial fusion and decreased cell proliferation. Mechanistic studies have shown that AIM2 downregulation promotes MFN2 upregulation, thereby enhancing mitochondrial fusion. Moreover, we found that mitochondrial fusion driven by AIM2 knockdown leads to a decrease of cellular reactive oxygen species (ROS) production, which further causes inactivation of the MAPK/ERK signaling pathway. Together, we discovered a novel function of AIM2 in promoting NSCLC development by regulating mitochondrial dynamics and revealed its underlying mechanism. Our work provides new intervention targets for the treatment of NSCLC.

Entities:  

Year:  2020        PMID: 32005973     DOI: 10.1038/s41388-020-1176-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model.

Authors:  I-Fen Chen; Fu Ou-Yang; Jen-Yu Hung; Jaw-Ching Liu; Hongying Wang; Shao-Chun Wang; Ming-Feng Hou; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

Review 2.  Mitochondrial fission and fusion dynamics: the long and short of it.

Authors:  S B Berman; F J Pineda; J M Hardwick
Journal:  Cell Death Differ       Date:  2008-04-25       Impact factor: 15.828

3.  Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors.

Authors:  Madhavika N Serasinghe; Shira Y Wieder; Thibaud T Renault; Rana Elkholi; James J Asciolla; Jonathon L Yao; Omar Jabado; Kyle Hoehn; Yusuke Kageyama; Hiromi Sesaki; Jerry E Chipuk
Journal:  Mol Cell       Date:  2015-02-05       Impact factor: 17.970

4.  Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation.

Authors:  Yuudai Kondo; Kentaro Nagai; Shingo Nakahata; Yusuke Saito; Tomonaga Ichikawa; Akira Suekane; Tomohiko Taki; Reika Iwakawa; Masato Enari; Masafumi Taniwaki; Jun Yokota; Sumio Sakoda; Kazuhiro Morishita
Journal:  Cancer Sci       Date:  2012-02-23       Impact factor: 6.716

5.  Differential expression of inflammasomes in lung cancer cell lines and tissues.

Authors:  Hui Kong; Yanli Wang; Xiaoning Zeng; Zailiang Wang; Hong Wang; Weiping Xie
Journal:  Tumour Biol       Date:  2015-04-25

Review 6.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

7.  Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.

Authors:  Justin E Wilson; Alex S Petrucelli; Liang Chen; A Alicia Koblansky; Agnieszka D Truax; Yoshitaka Oyama; Arlin B Rogers; W June Brickey; Yuli Wang; Monika Schneider; Marcus Mühlbauer; Wei-Chun Chou; Brianne R Barker; Christian Jobin; Nancy L Allbritton; Dale A Ramsden; Beckley K Davis; Jenny P Y Ting
Journal:  Nat Med       Date:  2015-06-24       Impact factor: 53.440

8.  ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells.

Authors:  Jianye Cai; Jiancheng Wang; Yinong Huang; Haoxiang Wu; Ting Xia; Jiaqi Xiao; Xiaoyong Chen; Hongyu Li; Yuan Qiu; Yingnan Wang; Tao Wang; Huimin Xia; Qi Zhang; Andy Peng Xiang
Journal:  Cell Death Dis       Date:  2016-11-10       Impact factor: 8.469

9.  Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment.

Authors:  Qian Yu; Minda Zhang; Qidi Ying; Xin Xie; Shuwen Yue; Bending Tong; Qing Wei; Zhaoshi Bai; Lingman Ma
Journal:  Cell Death Dis       Date:  2019-03-04       Impact factor: 8.469

10.  Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC.

Authors:  Ting-Fang Che; Ching-Wen Lin; Yi-Ying Wu; Yu-Ju Chen; Chia-Li Han; Yih-leong Chang; Chen-Tu Wu; Tzu-Hung Hsiao; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Oncotarget       Date:  2015-11-10
View more
  16 in total

Review 1.  AIM2 in health and disease: Inflammasome and beyond.

Authors:  Puja Kumari; Ashley J Russo; Sonia Shivcharan; Vijay A Rathinam
Journal:  Immunol Rev       Date:  2020-07-26       Impact factor: 12.988

2.  MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2.

Authors:  Yanhui Xu; Lei Zhang; Lilong Xia; Xinhai Zhu
Journal:  Oncol Lett       Date:  2021-04-08       Impact factor: 2.967

3.  Distinct axial and lateral interactions within homologous filaments dictate the signaling specificity and order of the AIM2-ASC inflammasome.

Authors:  Mariusz Matyszewski; Weili Zheng; Jacob Lueck; Zachary Mazanek; Naveen Mohideen; Albert Y Lau; Edward H Egelman; Jungsan Sohn
Journal:  Nat Commun       Date:  2021-05-12       Impact factor: 14.919

Review 4.  Inflammasomes in Cancer Progression and Anti-Tumor Immunity.

Authors:  Sebastian Lillo; Maya Saleh
Journal:  Front Cell Dev Biol       Date:  2022-04-20

Review 5.  The Emerging Relevance of AIM2 in Liver Disease.

Authors:  Beatriz Lozano-Ruiz; José M González-Navajas
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

6.  AIM2 inhibits colorectal cancer cell proliferation and migration through suppression of Gli1.

Authors:  Menglin Xu; Junfeng Wang; Haoran Li; Zhengrong Zhang; Zhengwu Cheng
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

7.  MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer.

Authors:  Shuhua Zhao; Xiaohong Zhang; Yuan Shi; Lu Cheng; Tingting Song; Bing Wu; Jia Li; Hong Yang
Journal:  J Exp Clin Cancer Res       Date:  2020-12-14

Review 8.  The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA.

Authors:  Vijay Kumar
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

9.  Absent in melanoma 2 suppresses gastric cancer cell proliferation and migration via inactivation of AKT signaling pathway.

Authors:  Dong Wang; Junwei Zou; Jun Dai; Zhengwu Cheng
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

10.  Deficiency in Aim2 affects viability and calcification of vascular smooth muscle cells from murine aortas and angiotensin-II induced aortic aneurysms.

Authors:  Markus Wortmann; Muhammad Arshad; Maani Hakimi; Dittmar Böckler; Susanne Dihlmann
Journal:  Mol Med       Date:  2020-09-15       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.